Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc. is the U.S. subsidiary of Hikma Pharmaceuticals PLC, a multinational pharmaceutical company headquartered in London, UK. The parent company was founded in Amman, Jordan, in 1978. Hikma Pharmaceuticals PLC is publicly traded on the London Stock Exchange (LSE: HIK). For the full year 2025, the parent company reported revenue of over $3.3 billion. The global company has over 9,500 employees. The U.S. headquarters is in Berkeley Heights, New Jersey.

Hikma is an operating company that develops, manufactures, and markets a broad portfolio of over 800 generic, branded generic, and in-licensed pharmaceutical products. The company's operations are divided into three main segments: Injectables, Branded, and what it terms "Hikma Rx" (its U.S. oral generics business). Its product lines cover a wide range of therapeutic areas, including oncology, pain management, respiratory, and anti-infectives. Hikma is a significant supplier of generic injectable medicines to hospitals in the U.S. and also provides oral solids, liquids, nasal sprays, and compounded sterile injectable products.

As an operating company, Hikma Pharmaceuticals USA Inc. appears in patent litigation as a defendant. The provided database shows the company with one tracked case as a defendant and zero as a plaintiff. This posture is typical for a generics manufacturer, which often faces patent infringement lawsuits from brand-name drug companies when seeking to market generic versions of patented drugs. This type of litigation, often under the Hatch-Waxman Act, is a standard part of the competitive landscape for pharmaceutical companies.

The single tracked case, Astellas Pharma Inc. et al. v. Hikma Pharmaceuticals USA Inc., filed in the U.S. District Court for the District of New Jersey, is consistent with this pattern. Pharmaceutical patent cases are frequently filed in Delaware and New Jersey, where many pharmaceutical companies are incorporated or have a significant presence. This case involves a major brand-name pharmaceutical firm, Astellas Pharma, suing Hikma, likely in connection with Hikma's plans to market a generic version of an Astellas product.